Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23961084 | 1.00 | KMT2A (0.45) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL25567604 | 1.00 | KMT2A (0.45) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL23930423 | 0.97 | KMT2A (0.47) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL24174659 | 0.83 | KMT2A (0.46) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL31181767 | 0.83 | KMT2A (0.46) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL24174962 | 0.82 | KMT2A (0.45) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL31011121 | 0.78 | MEN1 (0.48) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL30261153 | 0.77 | MEN1 (0.44) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL23961062 | 0.76 | TSHR (0.36) | KMT2AMEN1TSHRMAPK1ALDH1A1 | |
| SCHEMBL22167930 | 0.75 | HSD17B10 (0.45) | KMT2AMEN1TSHRALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139295-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| CN-119569706-A | Therapeutic compounds | 希四克斯探索有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-115667243-B | Tetrahydroisoquinoline compounds as NRF2 activators | 希四克斯探索有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-112996785-B | Therapeutic compounds | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20230167084-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230167084-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| EP-4139294-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4x Discovery Limited (GB) | 2023-03-01 | — | — | EP | disclosed |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2022-01-06 | — | — | US | disclosed |
| WO-2021214470-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214472-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214470-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
| CN-112996785-A | Therapeutic compounds | 希四克斯探索有限公司 | 2021-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | KMT2A 1158/4885MEN1 4307/4885TSHR 3995/4885 |
| US-20220002286-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | KMT2A 3198/4885MEN1 4234/4885TSHR 4051/4885 |
| US-20230167084-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | KMT2A 1158/4885MEN1 4307/4885TSHR 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.